Evofem Biosciences, INC 10-Q quarterly reports

Evofem Biosciences reports a $5.5 million quarterly loss and warns of substantial doubt regarding its ability to continue as a going concern despite expanding its product portfolio.

Evofem Biosciences reported Q3 2025 results, terminating its merger with Aditxt, facing substantial doubt about its ability to continue as a going concern, and navigating multiple debt defaults.

Evofem Biosciences reports continued operating losses and significant liquidity concerns, relying on a pending merger with Aditxt and new product commercialization to sustain operations.

Evofem Biosciences reports a net income of $956,000 for Q1 2025, but faces going concern uncertainties due to a working capital deficit and accumulated losses.

Evofem Biosciences has entered into new employment agreements with its CEO and CFO, outlining their roles, responsibilities, and compensation.

Evofem Biosciences' Q2 2024 results show a complex financial picture with increased product sales offset by significant operating expenses and strategic moves including a merger and acquisition.

Evofem Biosciences reported a net loss of $4.8 million for the first quarter of 2024, with product sales declining to $3.6 million, while also navigating a complex merger agreement with Aditxt.